Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
Summary
RATIONALE: Gene-modified lymphocytes may stimulate the immune system in different ways and stop tumor cells from growing. High-dose aldesleukin may stimulate lymphocytes to kill tumor cells. Vaccines made from a gene modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Giving gene-modified lymphocytes together with high-dose aldesleukin and vaccine therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gene-modified lymphocytes together with high-dose aldesleukin and vaccine therapy works in treating patients with progressive or recurrent metastatic cancer.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-08
- Completion
- 2009-08
Outcome
Outcome not reported
Stopped: “Terminated due to withdrawal of support from our collaborator.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 720000 iu/kg | Intravenous |
| Subject | anti-p53 T-cell receptor-transduced peripheral blood lymphocytes | Cell therapy | 1e+08 cells | Intravenous |
| Subject | anti-p53 T-cell receptor-transduced peripheral blood lymphocytes | Cell therapy | 5e+10 cells | Intravenous |
| Subject | autologous dendritic cell-adenovirus p53 vaccine | Cell therapy | 2e+08 cells | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |